ATLANTA, GA–(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB – News) (OTCQB: VSTA.OB – News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.

“VistaGen's work with human stem cell technology is groundbreaking,” said Sherri Snyder, Director of Marketing at MissionIR. “The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates.”

“We are pleased to bring MissionIR on board as our external investor relations partner,” said Shawn Singh, VistaGen's Chief Executive Officer. “The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development.”

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit www.MissionIR.com

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

View post:
VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) — Pathfinder Cell Therapy, Inc. (“Pathfinder,” or “the Company”) (OTCQB:PFND.PK – News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell (“PC”) technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

“We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant,” stated Dr. Franklin. “We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes.”

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, “If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development.”

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells (“PCs”) Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be “immune privileged,” and their effects appear to be independent of the tissue source of PCs. For more information please visit: www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

See more here:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

The treatment, a one-time IV infusion of bone marrow stem cells developed by Cleveland-based company Athersys Inc., can be delivered from 24 to 36 hours after a stroke.

“We have this huge population of patients with stroke that we're not doing anything for besides managing disability, preventing medical complications — nothing that we haven't been doing for 50 years,” said Dr. Cathy Sila, director of the Stroke and Cerebrovascular Center at the medical center and head of the trial there.

About 800,000 people have strokes every year, and 87 percent of those strokes are ischemic — the kind caused by a clot that blocks blood flow to the brain — according to the Centers for Disease Control and Prevention.

Clot-buster therapy, or tPA (for tissue plasminogen activator), has to be administered within 41/2 hours to help these patients, and most people don't make it to the hospital in time or aren't eligible for the treatment for some other reason, she said.

“We really do not have treatment for acute stroke,” said Sila.

Only 7 or 8 percent of people with acute stroke who could benefit from clot-buster therapy receive it now — despite public-awareness campaigns getting the word out about stroke symptoms and the importance of quick treatment.

UH, and 24 other sites across the country, will administer the treatment, called MultiStem to 140 patients over the next 18 months in the Phase 2 trial.

In theory, the stem cells would target the inflammation and damage that happen in the aftermath of a stroke, which researchers call the ischemic cascade. “It's like when you sprain your ankle, and it doesn't look so bad today, but tomorrow it's going to be bruised and swollen and hurt even worse,” Sila said.

In animal studies, treatment with the bone marrow stem-cell product at one, two and seven days post-stroke has reduced cell death and cut down on the inflammatory molecules that cause damage after the stroke.

“The [stem cells] appear to be a very important part of the body's natural healing process,” said Athersys Chairman and Chief Executive Gil Van Bokkelen.

The company is testing its product, adult stem cells harvested from healthy volunteers, which are then multiplied by a proprietary technique to treat heart attack and inflammatory conditions like graft-versus-host disease and inflammatory bowel disease.

MultiStem can be frozen for years and stored, so the product could be stocked in hospital pharmacies and used “off the shelf” as needed for stroke treatment, Van Bokkelen said.

Van Bokkelen would not give an exact cost for the treatment, but said that even if it cost as much as $50,000 per patient, it would still save an enormous amount of money in direct and indirect health care costs.

“The cost of stroke treatment in the U.S. is enormous,” he said. “It's in the tens of billions of dollars every year, and that number is expected to rise dramatically over the next few years with an aging population where more and more people are susceptible to stroke and heart disease.

“It's a huge market opportunity and it's also an area where it's kind of the quintessential unmet medical need — where most patients get the equivalent of medical hand-holding. That's just not satisfactory.”

The trial, which started recruiting patients nationwide at the end of December, will test the effectiveness and the safest dose of the treatment. Patients with stroke who are seen at the hospital's Case campus within 24 hours are eligible to participate. People who have already been treated with clot-buster medications are still eligible.

Aldagen Inc., a Durham, N.C.-based biopharmaceutical company, began a Phase 2 trial of its stem-cell treatment for stroke — ALD-401 — in June. That treatment, administered about two weeks after a stroke, is given through a catheter in the carotid artery.

“I don't know which of the two ways [of administering the cells] is going to be more effective, or which of the real variables it's going to depend on,” said Sila. “IV is always an easier route.”

So far, the MultiStem treatment appears to be safe. Sila said that she was reassured that patients in a leukemia trial who received multiple infusions of the stem cells showed no signs of transfusion reaction, a complication caused by the immune system attacking the donor cells.

There is the theory that brain tumors are brain stem cells gone bad, Sila said, and so flooding the brain with stem cells may not be a good thing: “It's very theoretical, and very improbable. Stem cells seem to exert most of their effects early on and then leave the body– they get cleared.”

Sila is cautiously optimistic about the therapy. She's acutely aware of the decades of failed treatments that have left patients with practically no help.

“We're at the beginning of this path. This is a lot of 'what-ifs,' but if it works . . . if this is effective, this would not be some trivial therapy. This could mean a potential treatment for 500,000 or 600,000 stroke victims a year.”

Originally posted here:
University Hospitals Case Medical Center and Athersys team up in national trial of stem cell therapy for stroke

A businessman is accused of stealing £16,500 from a trust fund set up to pay for his son to have stem cell treatment in China for motor neurone disease.

Cardiff Crown Court heard people raised £55,000 in sponsored runs after Julian Emms, 46, of Caerwent, Monmouthshire, established a charity for son Michael.

A blank cheque he obtained to take him on a £3,000 trip to New York was cashed for the larger amount, the jury heard.

Mr Emms denies fraud. The trial continues.

The jury was told on Tuesday that Michael Emms was diagnosed with motor neurone disease, a degenerative neurological condition, while in his teens.

Continue reading the main story

Emms went to their home and burned the cheques in front of them in a way which was deliberately theatrical”

End Quote Meirion Davies Prosecuting

The fundraising allowed him to go abroad for stem cell treatment but this failed.

After this, the jury was told, Mr Emms told his family he wanted £3,000 to fulfil Michael's dream of visiting New York.

He approached Michael's grandmother, Anne Brandon, one of the four people authorised to sign the charity's cheques, the court heard.

Meirion Davies, prosecuting, said: “Emms said he was booking a holiday to the USA for Michael and needed two cheques.

“One was for £3,000 for the holiday and the other was £300 for insurance.

“Mrs Brandon wrote the cheques out to a travel agency called Travelcare and signed them – but left them blank because Emms didn't know the exact amounts.”

Bio diesel processor

But Mrs Brandon and her husband David changed their minds and asked Mr Emms to return the cheques, Mr Davies said.

He said: “Emms went to their home and burned the cheques in front of them in a way which was deliberately theatrical.

“But one of them was in fact a blank piece of paper.”

The court was told the defendant already cashed the other cheque for £16,500 after changing the payee to “cash”.

Mr Emms was buying a £30,000 bio diesel processor at the time the cheque was cashed, the court was told.

The trial continues. Mr Emms denies fraud.

Michael Emms died in 2011, aged in his mid 20s.

Read more:
Man 'stole dying son's care cash'

ST. LOUIS, Mo., Feb. 21, 2012 /PRNewswire/ – Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has furthered its commitment to stem cell research, drug discovery and ADME/Toxicology by acquiring a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio. Sigma Life Science, leveraging its zinc finger protein platform and stem cell technology portfolio, is now poised to develop a new set of differentiated tools for both the drug discovery and preclinical research communities. These tools will include novel iPS-cells, iPS-cell derived primary cells, novel assays, custom cell line development and ADME/Toxicology services.  Under the terms of the agreement, iPS Academia Japan, Inc. (AJ) will receive a license fee from Sigma-Aldrich.

iPS cell technology can create pluripotent stem cells from the normal adult cells of a patient. Pluripotent stem cells are capable of differentiating into many specialized primary cell types needed for research, such as cardiomyocytes, hepatocytes, neurons, and muscle cells. With access to differentiated cells from patients with the condition of interest, or healthy human cells engineered to contain disease-specific genetics, researchers may obtain greater predictive accuracy than is possible with the in vitro models used currently in pharmaceutical research and preclinical studies.

“The pace of progress in iPS cell research has been breathtaking thanks to many scientists' strenuous efforts. With the non-exclusive license agreement that has been formed by Sigma-Aldrich, a global corporation in the life science field, and iPS Academia Japan, I expect that this move will further accelerate research and development using iPS cell technologies not only in the United States but also in the rest of the world,” said Professor Shinya Yamanaka, Director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University.

“Our license with Kyoto University grants us the freedom to operate under Kyoto University's induced pluripotent stem (iPS) cell patent portfolio in the increasingly important field of stem-cell based research and development. Researchers currently use primary cells derived from techniques that lack consistency and the ability to genetically engineer cells. Using the Kyoto iPS cell technology and our zinc finger protein technologies, we hope to generate stable, defined sets of cells and subsequently derived tissues whose predictive power will allow us to develop a new paradigm in assay development,” says David Smoller, Ph.D., Chief Scientific Officer at Sigma-Aldrich. “Thus, our Sigma-Aldrich scientists may be able to guide cells through the critical series of maturation steps — in ways no one has done previously — and also add reporter genes into these cells so that researchers can directly visualize the true biology of cellular processes.”

Sigma Life Science's new iPS cell-based technologies, along with its existing stem cell product portfolio of serum-free cell culture products, cell culture media, 3D matrices, growth factors, and antibodies, will provide uniquely comprehensive support for iPS cell-related research.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “has furthered,” “is poised to,” “can create,” “will,” “hope,” “may be able,” “expect,” “predictive” or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that iPS cells, iPS-cell derived primary cell lines, novel assays, or related custom services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated iPS cells, iPS-cell derived primary cell lines, novel assays, or related custom services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich:   Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than one million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology.  For more information about Sigma-Aldrich, please visit its award winning web site at www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries.

SOURCE Sigma-Aldrich Corporation

Back to top

RELATED LINKS
http://www.sigma-aldrich.com

Read more:
Sigma® Life Science Obtains Global License for Kyoto University's iPS Cell Patent Portfolio, Deepens Commitment to …

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. “Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety,” which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Dallas, TX (PRWEB) February 21, 2012

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. “Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety,” which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Treating arthritis with fat-derived stem cells has become commonplace in veterinary medicine over the past five years with over 7,000 horses and dogs treated by publication contributor Vet-Stem, a San Diego-based company. The objective of the joint Panamanian-US study was to determine feasibility of translating Vet-Stem's successful animal results into human patients.

Observing no treatment associated adverse reactions after one year, the team concluded that its protocol should be studied further to determine efficacy in the treatment of rheumatoid arthritis. Their publication details the rationale for the use of fat derived stem cells in treatment of autoimmune conditions and is freely available at: http://www.intarchmed.com/content/pdf/1755-7682-5-5.pdf

“Key to advancement of any medical protocol is transparent disclosure of rationale, treatment procedures and outcomes to the research community in a peer-reviewed and IRB-compliant manner,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and research team leader. “While we have previously published case studies on the use of fat stem cells in multiple sclerosis patients, and one rheumatoid arthritis patient, this is the first time that comprehensive follow-up has been completed for a larger cohort of patients,” he added.

An important distinction that separates this particular approach from those which are being explored by several international investigators is that the fat stem cells were not grown in a laboratory, affording a substantially higher level of safety and protocol practicality.

“This work signifies Panama's emergence into the burgeoning field of translational medicine,” commented Dr. Ruben Berrocal Timmons, the Panamanian Secretary of Science and publication co-author. “We are proud to have attracted and collaborated with internationally-renowned stem cell clinical researchers such as Dr. Michael Murphy and Dr. Keith March from the Indiana University School of Medicine Center for Vascular Biology and Medicine, Dr. Boris Minev from the University of California, San Diego Moores Cancer Center, Dr. Chien Shing Chen from Loma Linda University Behavioral Medicine Center and Dr. Bob Harman from Vet-Stem. By leveraging their vast, collective clinical experience with Panamanian scientific infrastructure and know-how, we are striving to develop effective, internationally recognized stem cell procedures that will be accepted the world over.”

The treatment procedure involves a mini-liposuction, collection of the fat's cellular component, processing to obtain a population of cells that includes stem cells, freezing the cells in preparation for quality control, and subsequent re-administration of the cells into patients.

The Panamanian-US group has previously shown that there is a specific type of T cell, called the T regulatory cell, associated with fat stem cells, which is capable of suppressing pathological immunity. Their current theory, which is described in detail in the publication: http://www.ncbi.nlm.nih.gov/pubmed/20537320, is that the T regulatory component of the fat is capable of slowing down or suppressing the “autoimmune” reaction, while the stem cell component causes formation of new tissue to replace the damaged joints.

About the Stem Cell Institute

Founded in 2006 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, the institute’s doctors treat carefully selected patients with spinal cord injury, osteoarthritis, heart disease, multiple sclerosis, rheumatoid arthritis and other autoimmune diseases. Doctors at The Stem Cell Institute have treated over 1000 patients to-date.

For more information on stem cell therapy:

Stem Cell Institute Web Site: http://www.cellmedicine.com

Facebook: http://www.facebook.com/stemcellinstitute

Blogger: http://www.adult-stem-cell-therapy.blogspot.com

Stem Cell Institute

Via Israel & Calle 66

Pacifica Plaza Office #2A

San Francisco, Panama

Republic of Panama

Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)

Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)

###

Jay Lenner
jdlenner@cellmedicine.com
1-800-980-7836
Email Information

See the original post:
Panamanian-US Scientific Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ – Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present “Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging.”  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes “regenerative therapies will become the next standard of care in treating many orthopedic conditions.” 

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes.  Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing. 

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells.  “We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval.  Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients.”

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. www.cellingbiosciences.com and www.spinesmithusa.com

Excerpt from:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit

See the rest here:
Qatari students to present research on stem cells

www.youtube.com/watch?v=Fv4oKw28-Rw

More:
Reuben Before and after Stem Cell Therapy – Video

www.youtube.com/watch?v=BeiZNVsTplU

Read more from the original source:
Using Your Own Fat Stem Cells For Arthritis, Sports Injuries and Autoimmune Disorders – Video